Peripheral nerve schwannoma: two cases exhibiting increased FDG uptake in early and delayed PET imaging.
We present two cases of peripheral nerve schwannoma which showed an increased accumulation of 2-deoxy-[(18)F] fluoro-D-glucose (FDG) in the tumors on positron emission tomography (PET) imaging acquired at both 1 h (early phase) and 2 h (delayed phase) after FDG injection. FDG-PET scans were performed with a dedicated PET scanner (HeadtomeV/ SET2400 W, Shimadzu, Kyoto, Japan) and the PET data analyzed the most metabolically active region of interest (ROI). We set the maximum standardized uptake value (SUV max) with a cut-off point of 3.0 to distinguish benign and malignant lesions. Although the mechanism responsible for the increased FDG uptake in benign schwannomas remains unknown, we discuss our findings in the context of tumor cellularity and briefly review other studies on the subject.
Department of Nuclear Medicine and Tracer Kintetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. hamada@tracer.med.osaka-u.ac.jp
Kenichiro
K
Hamada
Takafumi
T
Ueda
Ichiro
I
Higuchi
Atsuo
A
Inoue
Noriyuki
N
Tamai
Akira
A
Myoi
Yasuhiko
Y
Tomita
Katsuyuki
K
Aozasa
Hideki
H
Yoshikawa
Jun
J
Hatazawa
D000328:Adult; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging; D006801:Humans; D019042:Muscle Neoplasms / Q000000981:diagnostic imaging; D009442:Neurilemmoma / Q000000981:diagnostic imaging*; D010524:Peripheral Nervous System Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012186:Retroperitoneal Neoplasms / Q000000981:diagnostic imaging
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18